<DOC>
	<DOCNO>NCT01980810</DOCNO>
	<brief_summary>The purpose study determine whether albumine-bounded paclitaxel plus S-1 effective treatment advance gastric gastroesophageal junction adenocarcinoma .</brief_summary>
	<brief_title>First Line Chemotherapy Advanced Cancer</brief_title>
	<detailed_description>This phase II study design evaluate efficacy safety albumin-bounded paclitaxel combine S-1 first-line chemotherapy inoperable /or metastatic gastric gastroesophageal junction cancer.Primary endpoint overall response rate .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inoperable locally advanced , recurrent , and/or metastatic adenocarcinoma stomach gastroesophageal junction Adult patient &gt; =18 year age Performance Status Eastern Cooperative Oncology Group ( ECOG ) 02 ; At least one measurable disease ( accord RECIST ) Adequate bone marrow , renal liver function Previous chemotherapy advanced/metastatic disease Lack physical integrity upper gastrointestinal tract , malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>